• Latest Posts

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Norwegian Biotech Goes for Combination Therapies in Melanoma

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

Irish Biotech developing New Antibiotics attracts €58M in Series B Round

Shining new Light on how to control Cell Circuits

ADVERTISEMENT

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

Spanish Biotech Clears €2.7M Funding Round for its New Stroke Drug

Heptares receives €4.5M Milestone for New Migraine Drug Candidate

Italy is Getting its First-Ever Early Stage Biotech Fund for Tech Transfer

Danish Biotech Targeting Ion Channels Completes Private Placement

A Spanish Biosimilar of Amgen’s Blockbuster gets Ready for EU Approval

ADVERTISEMENT